Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals develops and commercializes products for central nervous system, metabolic critical care, oncology, and more. Products include Ryanodex, Belrapzo, Bendeka, EP-4104, PEMFEXY, EA-114, and Vasopressin injection. The company has licensing agreements with Combioxin, SA, and AOP Orphan Pharmaceuticals GmbH. Eagle also collaborates with Tyme Technologies for the development of SM-88 to treat breast cancer and sarcomas.
Overview
Strengths
- Return on invested capital has stayed above 15% in 3 of the last 4 years (latest 17.1%), a hallmark of a durable competitive advantage.
- Our discounted cash flow model points to 400% upside (target price 4.75 USD), and even our pessimistic growth scenario implies 400%: a margin of safety.
- Asset-light, cash-generative model: capital expenditure takes only 0.2% of revenue and free cash flow was positive in each of the last 4 years.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/E 0.3x vs. a median of 20.6x, P/FCF 0.2x vs. a median of 21.4x and EV/EBITDA 0.3x vs. a median of 12.9x.
- Shareholder-friendly capital allocation: the share count has shrunk by 1.5% a year over the last three years through buybacks.
- Improving fundamentals over the last year: return on assets up 12.2 points and asset turnover up 15.3%.
Weaknesses
- Unstable profitability: operating margin ranged from 2% to 26% over the last 4 years.
- Margin pressure: gross margin fell 5.4 percentage points last year, pointing to pricing pressure or rising costs.
- Earnings are projected to decline (-10.0% per year).
- Small company (enterprise value $20 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data